These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
3. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage. Jensen S; Steffensen MA; Jensen BA; Schlüter D; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(8):4152-64. PubMed ID: 24043891 [TBL] [Abstract][Full Text] [Related]
4. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961 [TBL] [Abstract][Full Text] [Related]
5. Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice. Holst PJ; Christensen JP; Thomsen AR J Immunol; 2011 Apr; 186(7):3997-4007. PubMed ID: 21357263 [TBL] [Abstract][Full Text] [Related]
7. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Oxenius A; Bachmann MF; Zinkernagel RM; Hengartner H Eur J Immunol; 1998 Jan; 28(1):390-400. PubMed ID: 9485218 [TBL] [Abstract][Full Text] [Related]
8. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. Grujic M; Holst PJ; Christensen JP; Thomsen AR J Gen Virol; 2009 Feb; 90(Pt 2):414-422. PubMed ID: 19141451 [TBL] [Abstract][Full Text] [Related]
9. Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection. Blass E; Aid M; Martinot AJ; Larocca RA; Kang ZH; Badamchi-Zadeh A; Penaloza-MacMaster P; Reeves RK; Barouch DH J Virol; 2018 Jun; 92(11):. PubMed ID: 29514912 [TBL] [Abstract][Full Text] [Related]
10. Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection. Bartholdy C; Stryhn A; Christensen JP; Thomsen AR J Immunol; 2004 Nov; 173(10):6284-93. PubMed ID: 15528367 [TBL] [Abstract][Full Text] [Related]
11. Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. Lee J; Hashimoto M; Im SJ; Araki K; Jin HT; Davis CW; Konieczny BT; Spies GA; McElrath MJ; Ahmed R J Virol; 2017 Mar; 91(5):. PubMed ID: 28003483 [TBL] [Abstract][Full Text] [Related]
12. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
14. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383 [TBL] [Abstract][Full Text] [Related]
15. Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. Hassett DE; Slifka MK; Zhang J; Whitton JL J Virol; 2000 Sep; 74(18):8286-91. PubMed ID: 10954526 [TBL] [Abstract][Full Text] [Related]
16. Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection. Holst PJ; Jensen BA; Ragonnaud E; Thomsen AR; Christensen JP PLoS One; 2015; 10(2):e0117242. PubMed ID: 25679375 [TBL] [Abstract][Full Text] [Related]
17. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Flatz L; Hegazy AN; Bergthaler A; Verschoor A; Claus C; Fernandez M; Gattinoni L; Johnson S; Kreppel F; Kochanek S; Broek Mv; Radbruch A; Lévy F; Lambert PH; Siegrist CA; Restifo NP; Löhning M; Ochsenbein AF; Nabel GJ; Pinschewer DD Nat Med; 2010 Mar; 16(3):339-45. PubMed ID: 20139992 [TBL] [Abstract][Full Text] [Related]
18. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Dolan BP; Gibbs KD; Ostrand-Rosenberg S J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172 [TBL] [Abstract][Full Text] [Related]
19. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Tatsis N; Fitzgerald JC; Reyes-Sandoval A; Harris-McCoy KC; Hensley SE; Zhou D; Lin SW; Bian A; Xiang ZQ; Iparraguirre A; Lopez-Camacho C; Wherry EJ; Ertl HC Blood; 2007 Sep; 110(6):1916-23. PubMed ID: 17510320 [TBL] [Abstract][Full Text] [Related]
20. Pseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization. Zhang C; Hu B; Xiao L; Liu Y; Wang P Hum Gene Ther Methods; 2014 Dec; 25(6):328-38. PubMed ID: 25416034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]